PARABILIS MEDICINES INC SEC Filings

Parabilis Medicines, Inc. officer Rohin Mhatre filed an initial Form 3 reporting holdings of stock options to purchase the company’s common stock. The filing lists three option grants with different exercise prices, share amounts and expiration dates.

One option covers 243,680 underlying shares at an exercise price of $3.14 per share expiring on February 17, 2036. Two additional options cover 181,948 and 38,988 underlying shares at an exercise price of $1.48 per share, both expiring on March 27, 2034. Footnotes explain that these options vest in monthly installments over multi‑year periods, contingent on continued service.

Parabilis Medicines, Inc. director Yeshwant Krishna filed an initial Form 3 to report beneficial ownership status in the company. The filing does not list any transactions, share acquisitions, or dispositions, and shows no derivative positions or holdings reported at this time.

Parabilis Medicines, Inc. insiders associated with Deerfield entities filed an initial Form 3 reporting indirect ownership of multiple preferred stock series that are convertible into voting common stock. The reported holdings are through Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P., with general partners and investment manager entities also listed as reporting persons.

The filing shows Series A, B, C and D Preferred Stock positions, each convertible into voting common stock at fixed ratios and at a conversion price of $0.0000 per share. According to the disclosure, each preferred share will automatically convert into common stock upon the closing of the company’s initial public offering of common stock, after giving effect to a 1‑for‑1.5389 reverse split completed on June 3, 2026.

The reporting persons state that, for Section 16 purposes, they disclaim beneficial ownership of the issuer’s securities except to the extent of any indirect pecuniary interest. The positions are therefore characterized as indirect holdings through the Deerfield funds rather than direct personal ownership.

Parabilis Medicines, Inc. General Counsel Teresa Jurgensen filed an initial ownership report showing holdings of stock options tied to the company’s common stock. She holds options covering 162,453 shares at an exercise price of $3.14 per share expiring on February 17, 2036, and options covering 214,438 shares at $1.88 per share expiring on September 4, 2034. According to the vesting schedules, 25% of one grant vested on August 1, 2025 with the balance vesting in 36 monthly installments, while the other grant vests in 48 equal monthly installments beginning on February 9, 2026, subject to her continued service.

Parabilis Medicines, Inc. director Richard Klausner reported his existing stock option holdings in this initial Form 3. He holds options over 48,736 shares of Common Stock with an exercise price of $1.88 per share that are fully vested and expire on December 10, 2034.

He also holds options over 21,273 shares of Common Stock with an exercise price of $4.62 per share, expiring on June 27, 2028. For this second grant, 25% vested on December 11, 2025, with the remaining shares vesting in thirty-six equal monthly installments, subject to his continued service.

Parabilis Medicines, Inc. officer Helen Huei-in Ho reported an initial holding of stock options on a Form 3. These options cover 519,851 shares of common stock at an exercise price of $4.09 per share and expire on April 20, 2036.

According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on April 13, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to her continued service. This filing discloses her equity-based compensation position rather than any buy or sell transaction.

Parabilis Medicines, Inc. director Edward M. Fitzgerald filed an initial ownership report showing his existing preferred stock and option positions in the company. The filing lists Series B, C and F Preferred Stock that are each convertible into Common Stock on fixed ratios and will automatically convert into specified numbers of Common shares immediately prior to the closing of the company’s initial public offering, without additional payment. Fitzgerald also holds stock options over Common Stock, including 32,490 shares at an exercise price of $3.14 per share expiring in 2036, 16,245 shares at $4.82 per share expiring in 2031, and 16,245 shares at $1.85 per share expiring in 2027. One option grant is fully vested, while another is scheduled to vest in 48 equal monthly installments starting February 24, 2026, subject to his continued service.

Parabilis Medicines, Inc. Chief Medical Officer Mohammed Fawzi Benzaghou reported his initial beneficial ownership on Form 3, showing two stock option awards for common stock. One option covers 243,680 underlying shares at an exercise price of $3.14 per share, expiring on February 17, 2036.

The second option covers 357,398 underlying shares at an exercise price of $2.42 per share, expiring on September 10, 2035. Vesting is time-based: one grant vests 25% on September 2, 2026 with the rest monthly over 36 months, and the other vests in 48 equal monthly installments starting February 9, 2026, subject to continued service.

Parabilis Medicines, Inc. director Jake Simson has filed an initial Form 3 ownership report. This filing identifies him as a director of the company but, in the provided data, shows no reported transactions or specific equity holdings. It serves as a baseline disclosure of his insider status.